Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.65 |
| ▸ | MTOR | P42345 | 5/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.61 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.45 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.45 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.45 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20725700 | 0.89 | PIK3CA (0.63) | PIK3CAPIK3CDMTORPIK3R1RICTOR | |
| SCHEMBL17053410 | 0.89 | PIK3CA (0.52) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL16639103 | 0.86 | PIK3CA (0.64) | PIK3CAPIK3CDMTORPIK3R1PIK3CB | |
| SCHEMBL17053422 | 0.85 | PIK3CA (0.60) | PIK3CAPIK3CDMTORPIK3R1RICTOR | |
| SCHEMBL16639080 | 0.82 | PIK3CD (0.76) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL16639145 | 0.80 | MTOR (0.61) | PIK3CAPIK3CDMTORPIK3R1RICTOR | |
| SCHEMBL16639069 | 0.79 | PIK3CD (1.00) | PIK3CAPIK3CDMTORPIK3R1PIK3CB | |
| SCHEMBL20725680 | 0.79 | PIK3CD (0.80) | PIK3CAPIK3CD | |
| SCHEMBL16639139 | 0.78 | PIK3CA (0.62) | PIK3CAPIK3CDMTORPIK3R1RICTOR | |
| SCHEMBL17053417 | 0.78 | PIK3CD (0.58) | PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860181-B1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| EP-2860181-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES THEREOF | Shanghai Yingli Science and Technology Co., Ltd (CN) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CD 2/4885MTOR 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.